Related references
Note: Only part of the references are listed.Corneal Epithelial Cell Viability Following Exposure to Ophthalmic Solutions Containing Preservatives and/or Antihypertensive Agents
Jess T. Whitson et al.
ADVANCES IN THERAPY (2012)
Besifloxacin Ophthalmic Suspension 0.6% Administered Twice Daily for 3 Days in the Treatment of Bacterial Conjunctivitis in Adults and Children
Jesse DeLeon et al.
CLINICAL DRUG INVESTIGATION (2012)
Corneal Neurotoxicity Due to Topical Benzalkonium Chloride
Joy Sarkar et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2012)
Monitoring Antibiotic Resistance in Ocular Microorganisms: Results From the Antibiotic Resistance Monitoring in Ocular MicRorganisms (ARMOR) 2009 Surveillance Study
Wolfgang Haas et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2011)
Topoisomerase Mutations That Are Associated with High-Level Resistance to Earlier Fluoroquinolones in Staphylococcus aureus Have Less Effect on the Antibacterial Activity of Besifloxacin
Christine M. Sanfilippo et al.
CHEMOTHERAPY (2011)
Pharmacokinetic Comparisons of Bromfenac in DuraSite and Xibrom
Erwin C. Si et al.
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS (2011)
Safety and Tolerability of Besifloxacin Ophthalmic Suspension 0.6% in the Treatment of Bacterial Conjunctivitis Data from Six Clinical and Phase I Safety Studies
Timothy L. Comstock et al.
CLINICAL DRUG INVESTIGATION (2010)
Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae
Wolfgang Haas et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
Besifloxacin, a Novel Fluoroquinolone, Has Broad-Spectrum In Vitro Activity against Aerobic and Anaerobic Bacteria
Wolfgang Haas et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Besifloxacin Ophthalmic Suspension 0.6% in Patients With Bacterial Conjunctivitis: A Multicenter, Prospective, Randomized, Double-Masked, Vehicle-Controlled, 5-Day Efficacy and Safety Study
Paul Karpecki et al.
CLINICAL THERAPEUTICS (2009)
Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis
Michael E. Tepedino et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli
Emmanuelle Cambau et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
Ocular Pharmacokinetics of Besifloxacin Following Topical Administration to Rabbits, Monkeys, and Humans
Joel W. Proksch et al.
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS (2009)
Ocular Surface Distribution and Pharmacokinetics of a Novel Ophthalmic 1% Azithromycin Formulation
Esen Karamursel Akpek et al.
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS (2009)
Development of a Topical Polymeric Mucoadhesive Ocular Delivery System for Azithromycin
Lyle M. Bowman et al.
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS (2009)
Efficacy and Safety of Besifloxacin Ophthalmic Suspension 0.6% Compared with Moxifloxacin Ophthalmic Solution 0.5% for Treating Bacterial Conjunctivitis
Marguerite B. McDonald et al.
OPHTHALMOLOGY (2009)
Ocular toxicity of fluoroquinolones
Andrew M. Thompson
CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2007)
Phase 3 safety comparisons for 1.0% azithromycin in polymeric mucoadhesive eye drops versus 0.3% tobramycin eye drops for bacterial conjunctivitis
Eugene Protzko et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2007)
Antimicrobial efficacy of gatifloxacin and moxifloxacin with and without benzalkonium chloride compared with ciprofloxacin and Levofloxacin against methicillin-resistant Staphylococcus aureus
J. M. Blondeau et al.
JOURNAL OF CHEMOTHERAPY (2007)
Nonclinical pharmacodynamics, pharmacokinetics, and safety of BOL-303224-A, a novel fluoroquinolone antimicrobial agent for topical ophthalmic use
Keith W. Ward et al.
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS (2007)
Comparison of toxicological profiles of benzalkonium chloride and polyquaternium-1:: An experimental study
Antoine Labbe et al.
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS (2006)
Share Paper
